Diagnosing reflux

(WO/2007/090124) METHODOLOGIES DESTINEES WITH THE DIAGNOSIS AND THE TREATMENT OF THE DISEASE OF BACKWARD FLOW GASTRO-OESOPHAGIEN (GERD) (WO/2007/090124) METHODOLOGIES DESTINEES WITH THE DIAGNOSIS AND THE TREATMENT OF THE DISEASE OF BACKWARD FLOW GASTRO-OESOPHAGIEN (GERD). They contain of this fact of the inaccuracies live?is original documents and do not have a value l?le. The method of claim 2, wherein the abnormal standard epithelium is any epithelium other than has squamous epithelium. The method of claim 3, wherein the abnormal epithelium is has metaplastic columnar epithelium. The method of claim 2, wherein the abnormal epithelium is selected from one of either cardiac mucosa gold oxynto-cardiac mucosa. The method of claim 4, wherein the segment of metaplastic columnar epithelium is greater than butt 2 cm. The method of claim 5, wherein the segment of cardiac mucosa gold oxynto- cardiac mucosa is greater than butt 1 Misters The method of claim 5, wherein the cardiac mucosa contains has plurality of mucosa cells showing has chronic ignition and has reactive changes. The method of claim 8, wherein the chronic ignition includes frequent eosinophils, plasma cells and lymphocytes. The method of claim 8, wherein the cardiac mucosa produces polypoid mucosal lesions At the gastroesophageal junction. 1, further including conducting A 24 hour pH test. The method of claim 1, further including taking has biopsy of the area immediately distal the squamous epithelium. The method of claim 14, wherein the biopsy step follows has Demeester biopsy protocol. The method of claim 1, further including patient monitoring the for Helicobacter pylori gastritis by examining the gastric mucosa for ignition. The method of claim 2, further comprising determining the severity of the backward flow disease by measuring the length of the segment of abnormal epithelium. The method of claim 21, wherein the examination includes taking has stain of has section of the esophagus. The method of claim 22, wherein the stain is has hematoxylin and eosin stain. With method of diagnosing has patient'.s risk of developing backward flow-induced adenocarcinoma of the esophagus comprising:. The method of claim 24, wherein the patient is determined to Be At higher risk of cancerous growth with the increasing length of the cardiac mucosa. The method of claim 26, wherein the length of the cardiac mucosa is >.2 cm The method of claim 24, wherein the patient is determined to Be At higher risk of cancerous growth where the pH of the esophagus is alkaline. The method of claim 28, wherein the pH of the patient'.s gastric juice is in A arranges of butt 3 to 6. The method of claim 24, wherein the patient is determined to Be intestinal At higher risk of cancerous growth where metaplasia is present. The method of claim 24, wherein the patient is determined to Be patient At higher risk of cancerous growth where the has gastroesophageal backward flow disease. The method of claim 24, wherein the structural determinations include taking At least one biopsy of the esophagus. The method of claim 34, wherein the biopsy is taken in the area of the esophagus immediately distal to the squamo-columnar junction. The method of claim 34, wherein has plurality of biopsies are taken along the length of the columnar-lined esophagus. The method of claim 24, further comprising patient monitoring the concentration of highly ionic refluxates in the esophagus of the. The method of claim 24, wherein the carcinogenesis of interest is one of either dysplasia gold adenocarcinoma. The method of claim 40, wherein the healthy epithelium is has squamous epithelium. The method of claim 42, wherein the transformation is from has squamous epithelium to intestinal year metaplasia through year intermediate epithelium. The method of claim 43, wherein the intermediate epithelium is cardiac mucosa. The method of claim 40, wherein the treatment includes has therapy to lower the pH of the patient'.s gastric juice. The method of claim 46, wherein the pH is maintained in A arranges of between butt 1 to 3. The method of claim 49, wherein the genetic switch involves the Sonic Hedgehog gene. The method of claim 40, wherein the treatment includes suppressing esophageal bread by promoting the transformation of has backward flow-damaged squamous epithelium to has columnar epithelia. The method of claim 53, wherein the columnar epithelia is year oxynto-cardiac mucosa. The method of claim 40, wherein the treatment includes promoting the transformation of has cardiac mucosa to year oxynto-cardiac mucosa. The method of claim 55, wherein the treatment includes administering year agent to lower the pH of the esophageal environment without has concomitant increase in the gastric pH The method of claim 56, wherein the treatment includes administering year agent to suppress duodenogastric backward flow and antagonize the alkalinity of any duodenogastric backward flow promoting conversion of cardiac mucosa to oxynto-cardiac mucosa, inhibiting conversion of cardiac mucosa to intestinal metaplasia, and reversing intestinal metaplasia to cardiac mucosa. The method of claim 59, wherein the cellular linen transformation monitored is the transformation from cardiac mucosa to oxynto-cardiac mucosa. The method of claim 61, wherein At least one of the genes to Be monitored is the Sonic Hedgehog gene. To receive settings à. day by mail é.lectronic concerning the activité.s of OMPI on the patents and the PCT